PMID- 24356188
OWN - NLM
STAT- MEDLINE
DCOM- 20140506
LR  - 20131220
IS  - 0040-5957 (Print)
IS  - 0040-5957 (Linking)
VI  - 68
IP  - 6
DP  - 2013 Nov-Dec
TI  - [Adverse effects of sulfasalazine: discussion of mechanism and role of 
      sulfonamide structure].
PG  - 369-73
LID - 10.2515/therapie/2013064 [doi]
AB  - Sulfasalazine is widely used in the treatment of chronic inflammatory bowel 
      disease (IBD) and certain rheumatic diseases. However, its use is associated with 
      a high rate of adverse effects (AEs) which can be cutaneous, hematological, 
      renal, hepatic, gastrointestinal or neurological. The aim of our study was to 
      collect all cases of AEs suspected to be associated with the use of sulfasalazine 
      in patients hospitalized in the department of Gastroenterology from the Hospital 
      Hedi Chaker of Sfax (Tunisia) for a period of 5 years and to search the 
      incriminated fraction (sulfonamide or salicylate). Our study population included 
      69 patients who received sulfasalazine for the treatment of IBD. We collected, in 
      23 patients (33%), 25 AEs suspected to be related to sulfasalazine. Cutaneous and 
      hematological reactions are the most common. The subsequent administration of 
      mesalazine was performed in 15 patients. It was well tolerated in 14 patients. So 
      we were suspecting probably the responsibility of sulfonamide fraction in these 
      cases. The mechanism of sulfasalazine induced AEs may be toxic or immunoallergic 
      with the possibility of a cross-reaction with the other antimicroacterial 
      sulfonamides.
CI  - (c) 2013 Societe Francaise de Pharmacologie et de Therapeutique.
FAU - Atheymen, Rim
AU  - Atheymen R
AD  - Laboratoire de Pharmacologie, Faculte de Medecine, Sfax, Tunisie.
FAU - Affes, Hanen
AU  - Affes H
AD  - Laboratoire de Pharmacologie, Faculte de Medecine, Sfax, Tunisie.
FAU - Ksouda, Kamilia
AU  - Ksouda K
AD  - Laboratoire de Pharmacologie, Faculte de Medecine, Sfax, Tunisie.
FAU - Mnif, Leila
AU  - Mnif L
AD  - Service de Gastroenterologie, Hopital Hedi Chaker, Sfax, Tunisie.
FAU - Sahnoun, Zouheir
AU  - Sahnoun Z
AD  - Laboratoire de Pharmacologie, Faculte de Medecine, Sfax, Tunisie.
FAU - Tahri, Nabil
AU  - Tahri N
AD  - Service de Gastroenterologie, Hopital Hedi Chaker, Sfax, Tunisie.
FAU - Zeghal, Khaled Mounir
AU  - Zeghal KM
AD  - Laboratoire de Pharmacologie, Faculte de Medecine, Sfax, Tunisie.
FAU - Hammami, Serria
AU  - Hammami S
AD  - Laboratoire de Pharmacologie, Faculte de Medecine, Sfax, Tunisie.
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Effets indesirables de la sulfasalazine : discussion de leur mecanisme et du role 
      de la composante sulfamidee.
DEP - 20131220
PL  - France
TA  - Therapie
JT  - Therapie
JID - 0420544
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 3XC8GUZ6CB (Sulfasalazine)
RN  - 4Q81I59GXC (Mesalamine)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Cross Reactions
MH  - Female
MH  - Hospitalization
MH  - Humans
MH  - Inflammatory Bowel Diseases/*drug therapy
MH  - Male
MH  - Mesalamine/*adverse effects/therapeutic use
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Sulfasalazine/*adverse effects/therapeutic use
MH  - Tunisia
EDAT- 2013/12/21 06:00
MHDA- 2014/05/07 06:00
CRDT- 2013/12/21 06:00
PHST- 2013/05/13 00:00 [received]
PHST- 2013/09/20 00:00 [accepted]
PHST- 2013/12/21 06:00 [entrez]
PHST- 2013/12/21 06:00 [pubmed]
PHST- 2014/05/07 06:00 [medline]
AID - th132172 [pii]
AID - 10.2515/therapie/2013064 [doi]
PST - ppublish
SO  - Therapie. 2013 Nov-Dec;68(6):369-73. doi: 10.2515/therapie/2013064. Epub 2013 Dec 
      20.